slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 67,561-67,590
Pages 10,126
Rows per page 30
Component
67,561-67,590 of 303,780
13
The chart shows a clear shift from corporate-dominated M&A to increased VC and PE participation over the decade.Mergers and Acquisitions in LatAm: Evolution and prospects · L.E.K.
Consulting deck Strategy consulting Beat · SatisfactionLoop · Zoom In1 hit
18
Mergers and Acquisitions in LatAm: Evolution and prospectsMergers and Acquisitions in LatAm: Evolution and prospects · L.E.K.
Consulting deck Strategy consulting 1 hit
19
Slide 19 from an L.E.K. consulting deck.Mergers and Acquisitions in LatAm: Evolution and prospects · L.E.K.
Consulting deck Strategy consulting 1 hit
20
The chart shows a significant decline in 2023 compared to previous years.Mergers and Acquisitions in LatAm: Evolution and prospects · L.E.K.
Consulting deck Strategy consulting 1 hit
21
The slide uses a stacked bar chart to show the composition of M&A deals in Mexico over a decade, accompanied by a table of CAGR metrics and a list of qualitative highlights.Mergers and Acquisitions in LatAm: Evolution and prospects · L.E.K.
Consulting deck Strategy consulting 1 hit
25
Mergers and Acquisitions in LatAm: Evolution and prospectsMergers and Acquisitions in LatAm: Evolution and prospects · L.E.K.
Consulting deck Strategy consulting 1 hit
26
Slide 26 of an L.E.K. deck.Mergers and Acquisitions in LatAm: Evolution and prospects · L.E.K.
Consulting deck Strategy consulting Beat · Action1 hit
27
The chart highlights a shift in sector focus for M&A activity in Colombia over a decade.Mergers and Acquisitions in LatAm: Evolution and prospects · L.E.K.
Consulting deck Strategy consulting Beat · Action1 hit
28
The chart shows a clear decline in total deal volume over the decade, with a shift in investor composition.Mergers and Acquisitions in LatAm: Evolution and prospects · L.E.K.
Consulting deck Strategy consulting Beat · Action1 hit
29
The chart shows a clear peak in deal volume in 2018 followed by a decline, with a specific callout for a 30% drop between 2021 and 2023.Mergers and Acquisitions in LatAm: Evolution and prospects · L.E.K.
Consulting deck Strategy consulting Beat · Action1 hit
30
The chart highlights the dominance of the Oil, Gas, Energy, and Mining sector, while TMT's share increases over time. A callout indicates a -24% change between 2021 and 2022.Mergers and Acquisitions in LatAm: Evolution and prospects · L.E.K.
Consulting deck Strategy consulting Beat · Action1 hit
31
Mergers and Acquisitions in LatAm: Evolution and prospectsMergers and Acquisitions in LatAm: Evolution and prospects · L.E.K.
Consulting deck Strategy consulting 1 hit
32
Mergers and Acquisitions in LatAm: Evolution and prospectsMergers and Acquisitions in LatAm: Evolution and prospects · L.E.K.
Consulting deck Strategy consulting 1 hit
02
Perspectives on US Healthcare Inflation Insights from L.E.K. ConsultingPerspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Situation & Context1 hit
03
The chart uses a dual-line plot to show the divergence between healthcare and general inflation, with a shaded region for the Great Recession.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Problem & ComplicationLoop · Mece Breakdown1 hit
04
Data shows hospital-related services as the primary driver of recent healthcare inflation.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Problem & ComplicationLoop · Mece Breakdown1 hit
05
The chart uses a grouped bar structure to compare annual inflation trends across 12 specific healthcare sub-segments.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Problem & ComplicationLoop · Mece Breakdown1 hit
06
The slide uses a dual-axis chart combining line graphs for cumulative change and bar charts for 12-month percentage change.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Evidence & Proof1 hit
07
The slide uses a side-by-side comparison framework to contrast opposing economic forces.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
08
The chart highlights a divergence between healthcare inflation and general inflation, with a specific forecast range for healthcare.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
11
The slide uses a vertical arrow to indicate a progression from 'Nearer-term/Lower potential impact' to 'Longer-term/Greater potential impact'.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Solution & Approach1 hit
12
Perspectives on US Healthcare Inflation Insights from L.E.K. ConsultingPerspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting 1 hit
01
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Situation & Context1 hit
02
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Situation & Context1 hit
03
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Situation & Context1 hit
04
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Situation & Context1 hit
07
The slide uses a comparative bar chart structure to contrast high growth in China (29% CAGR) against stable growth in the U.S. (3% CAGR).Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Problem & Complication1 hit
08
The slide uses a honeycomb layout to group regulatory initiatives. Color coding indicates the nature of the policy (R&D, Registration, Pricing/Market Access, Commercialization).Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Problem & Complication1 hit
09
The slide uses stacked bar charts to show the composition of clinical trials by phase (I, II, III) for China and the US.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Problem & Complication1 hit
10
Data refers to enterprises above designated annual revenue size (>20M RMB). Exchange rate 6.25 used.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Problem & Complication1 hit